Studies of the pattern of urinary excretion of pethidine and promazine, and of a selection of their primary metabolites, suggest that metabolism of these agents is rendered somewhat deficient during pregnancy, during the neonatal period and under the influence of certain oral contraceptive agents. Some general conclusions have been drawn from these observations. Increased caution in the administration of drugs to patients known to be taking oral contraceptives is recommended.
It is well known that in some species (notably the rat) subsequent to puberty there is a marked sex-dependent variation in the rate at which the animal can metabolize certain drugs (Poe, Suchy and Witt, 1936; Hoick et al., 1937; Hoick, 1949; Murphy and Du Bois, 1958; Inscoe and Axelrod, 1960; Booth and Gillette, 1962) . No evidence has yet been presented that this applies to humans. It is also appreciated that a disturbance of the normal endocrine equilibrium can influence the pattern of response of an animal to some drugs (Bousquet, Rupe and Miya, 1965) . It would not be surprising if this applied to the changes evoked during pregnancy. Indeed, it is the personal observation of one of us (J.S.C.) that there is, in informed clinical circles, a slowly-growing impression that pregnancy in the human imposes a modification in the woman's response to drugs. Recently, Shnider (1965) has confirmed that the pregnant patient at term has a relatively low serum cholinesterase, the inference being that she is in consequence more susceptible than is the non-pregnant to the action of suxamethonium. King (1964) has noted that, following the administration of a standard dose of pentobarbitone, the pregnant rat exhibits a higher level of concentration of the drug in brain tissue and in blood than does the non-pregnant animal.
Our interest in these matters was aroused by observations made during investigations into the placental transfer of promazine (Sparine) (Crawford and Rudofsky, 1965a, b) and pethidine (Crawford and Rudofsky 1965c) . The subjects in these studies each received, intravenously, a standard dose of one of the drugs, and the quantity of major metabolites of the drug in the urine passed during the subsequent 24 or 48 hours was measured. We noted that there was a marked difference between the pattern of excretion of metabolites by the pregnant subjects (and by their infants) and that found in the non-pregnant (male and female) controls. Briefly, it appeared that the pregnant patients and the neonates excreted a preponderance of unchanged pethidine over norpethidine, whereas the converse applied to the non-pregnant subjects: further, the mothers and infants excreted a considerably greater quantity of a received dose of promazine either unchanged or in a minimally metabolized form than did the non-pregnant adults. We considered the contrast to be striking enough to warrant further investigation, and at least an initial attempt to define more closely the factors contributing to its production. We describe here our preliminary survey.
MATERIAL AND METHODS
The same drugs (promazine and pethidine) as in the original investigations were used, as we were satisfied that our methods of assay provided reasonably reliable data, and also because we could then include in the survey the results previously obtained.
Each subject received pethidine 50 mg and/or promazine 50 mg intravenously (dissolved in 5-6 ml solute and injected slowly). A 48-hour collection of urine was obtained from all subjects except from those who had provided the original "placental transfer of promazine" study (Crawford and Rudofsky, 1965a) ; from these latter (pregnant and non-pregnant) only a 24-hour sample of urine was obtained.
Eight groups of subjects were studied.
(1) Pregnant. Promazine 50 mg was administered to 23 pregnant patients shortly before delivery, and a 24-hour sample of urine obtained. Five women received pethidine 50 mg intravenously shortly before delivery, and a 48-hour specimen of urine was obtained from each subject. One further patient, who had unwittingly been chosen as a control subject in the original pethidine-transfer study (Crawford and Rudofsky, 1965c) was 16 weeks pregnant when she received pethidine 50 mg intravenously.
(2) Neonates. Urine from all the male infants of the term pregnancies was assayed, but as the possibility remains that the composition of the neonatal urine is governed in part by maternallyproduced metabolites which crossed the placenta, the results will be disregarded here. However, two 1-day-old infants were given, intramuscularly, promazine (respectively 1.5 mg and 2.0 mg), and a further two received, intra-muscularly, pethidine (1.0 mg each, with the addition of an appropriate amount of levallorphan), and 48-hour samples of urine were obtained from these (Crawford and Rudofsky 1965a, c) .
(3) Patients for hystero-oophorectomy. Five patients, none of whom had reached the menopause, and who were due to have both uterus and ovaries removed, were chosen for study. Two days prior to operation, each received promazine 50 mg intravenously, and subsequently provided a 48-hour collection of urine. On the fifth postoperative day, a repeat dose of promazine 50 mg was given to each patient, and a further 48-hour sample of urine collected. One of these patients had received no supportive hormone therapy subsequent to operation, but on the fourth and fifth postoperative days the remaining four patients each received an intramuscular injection of 20 mg crystalline oestradiol dissolved in 1.0 ml 10 per cent N,NDMA (N^N-dimethylacetamide) in propylene glycol.* On the tenth postoperative day a further 50-mg dose of promazine was given to each patient, and a 48-hour urine collection made. Those who had previously been given oestradiol received no additional hormone therapy prior to the third dose of promazine; the fifth patient received oestradiol 20 mg intramuscularly on the ninth and tenth postoperative days. The lack of material-balance in this pan of the study was due to administrative difficulties.
(4) Postmenopausal subjects not receiving supportive therapy. Four elderly postmenopausal subjects, in good general health, who were not in receipt of supportive hormone therapy, were given a mixture of promazine 50 mg and pethidine 50 mg intravenously. A 48-hour specimen of urine was collected.
(5) Postmenopausal on stilboestrol. One patient who had undergone hystero-oophorectomy 3 years previously and who had since been taking stilboestrol 0.25 mg daily, was given promazine 50 mg and pethidine 50 mg. In addition, three patients received the mixture on the ninth day following hystero-oophorectomy, each of them having been taking stilboestrol 0.5 mg daily since the fifth postoperative day.
(6) Subjects taking oral contraceptives. Five healthy volunteers were given promazine 50 mg and pethidine 50 mg intravenously and contributed a 48-hour collection of urine. Four of these subjects had regularly been taking Enavid-E (norethynodrel 5 mg, mestranol 0.075 mg) over the usual 20-day cycle for, respectively, 6 months, 4 years, 5 years, and 7 years. The fifth subject had been on Norinyl (norethindrone 2 mg mestranol 0.1 mg) for the previous 5 months, but had, prior to changing to Norinyl, been on a variety of oral contraceptive agents.
(7) Males. Four healthy male volunteers were each given a combined dose of promazine 50 mg plus pethidine 50 mg on three occasions, and a 48-hour collection of urine was made after each. The first injection provided the control reading. Before the second injection, two of the volunteers took diethyl stilboestrol 5 mg by mouth daily for 14 days, and the other two ingested progesterone 10 mg daily for the same period. After allowing a recovery interval of 9 days, the volun- teers took the alternate hormone for 14 days and then received the third injection of promazine plus pethidine. (8) "Non-obstetric controls". Four relatively young women, in good general health, not pregnant, and not taking oral contraceptives, were given pethidine 50 mg during the course of a minor gynaecological procedure and a 48-hour output of urine was collected. They formed a control group for the placental transfer study, and are referred to here as the "non-obstetric controls". A similar group of different individuals (seven) had provided a series of controls during the promazine study, and in addition, three male subjects who were undergoing minor surgery were included. From these latter ten "non-obstetric controls", only a 24-hour urinary output collection was obtained.
Finally, it must be made plain that in none of the cases referred to here was a subsidiary dose of the drug under consideration (or of an agent chemically related to it) administered to the subject during the period extending from at least 48 hours prior to the start of the study to the conclusion of the collection of urine. In the cases of the neonates who received the drugs directly, the respective mothers had not received the pertinent agents during labour or delivery.
Laboratory.
As indicated in our previous report (Crawford and Rudofsky, 1965a) , the method described by Wiser, Knebel and Seifter (1960) was used to assay promazine and its primary metabolites. The method permits the identification of two of the three primary metabolites of the drug (the sulphoxide and the monomethyl compound) described by Walkenstein and Seifter (1959) . We thus identified in each specimen of urine the quantity of "unchanged" promazine and the quantity of what we will term, with some licence, "major metabolites".
Pethidine and its demethylated metabolite, norpethidine, were assayed using the method described by Burns and associates (1955) . We did not measure the quantity of pethidinic acid and of norpethidinic acid; but, as the reaction of urine in most of the specimens was on the acid side, we do not consider the omission to be grave, our interest being mainly in the ratio between the quantities of unchanged drug and demethylated compound.
All assays were performed in duplicate and read against appropriately selected blanks.
RESULTS

Pethidine.
The findings in respect to pethidine are presented in table I.
The total amount of pethidine and norpethidine excreted by the adult subjects appeared to provide little information of interest. The two newborn infants excreted a rather greater proportion of the drug in identifiable form.
The relationship between the quantity of pethidine and the amount of norpethidine found to be excreted by each subject offers more interesting data. All 6 pregnant patients, 4 of the 5 subjects on oral contraceptives, and the 2 neonates were found to have passed more of the unchanged pethidine than of the demethylated compound. The reverse held true for the 4 "non-obstetric controls", for 3 of the 4 postmenopausal patients who had received no hormone therapy, and for the 3 oophorectomized patients who were studied after having received stilboesterol from the fifth to the ninth postoperative day. The postmenopausal subject who had been taking stilboestrol for 3 years excreted a dominance of unchanged pethidine. Statistical analysis reveals that the combined group of 6 pregnant patients and 5 subjects taking oral contraceptives excreted significantly more of the drug unchanged, rather than as the demethylated compound, than did the combined groups of postmenopausal subjects not on stilboestrol (4), post-oophorectomy and on stilboestrol for only a few days (3), and "nonobstetric controls" (4) (SE of the difference between the means 7.55; difference between the means 30.43).
One of the male volunteers ((a) in table I) consistently excreted more pethidine than norpethidine, and the reverse held for another volunteer (d). Subsequent to taking a course of stilboestrol, and, similarly, of progesterone, each male volunteer excreted a greater preponderance of pethidine in its unchanged form. The paucity of data obtained from thin small series of studies on male subjects prevented statistical evaluation of the results. Promazine.
The data respecting the studies with promazine are summarized in table n. The relationship between the amount of "unchanged" promazine excreted and the quantity of identified primary metabolites excreted appears not to differ markedly between one group of subjects and another, despite a certain amount of scatter among the individual results. On average, approximately 70-80 per cent of the identified products are present as "major metabolites". This suggests that if there is any interference with the metabolism of promazine by the agencies under consideration, it occurs after the initial degradation processes of oxidation and demethylation.
Analysis of the results in respect of the total quantity of identified products recovered from the urine is complicated by the fact that, during our initial study, we collected only a 24-hour urine sample from the pregnant patients and from the "non-obstetric" controls. However, in the course of that earlier study (Crawford and Rudofsky, 1965a) we did note that the neonates excreted, during the second half of the 48-hour period, as much promazine plus "major metabolites" as they had excreted during the first 24-hour period. It seems not unreasonable, therefore, to suggest that the figures in the second column of table II, respecting pregnant subjects and "non-obstetric", could be doubled to represent a 48-hour urinary output.
Comparison of the results derived from the obstetric patients (23) with those from the 10 "non-obstetric controls" (24-hour samples of urine from both groups) reveals that the former excreted significantly more identified products (differences between the means 2.81; SE of difference 0.556). The significance of difference is maintained when only the female "non-obstetric controls" are considered.
The two neonates excreted a comparatively large quantity of identified products during the 48-hour period of urine collection. The ratio of unchanged promazine to "major metabolites" was well within the range found among the adult subjects.
Significantly more identified products of promazine were found in the urine of the 5 subjects who were taking oral contraceptives, than was assayed in the urine samples obtained from the 7 patients who were studied before and shortly after hystero-oophorectomy (15 samples of urine: difference between the means 2.55; SB of difference 0.92).
The studies conducted on the male volunteers provided no data of statistical significance, although it is possibly noteworthy that 3 of the 4 subjects excreted more identified products subsequent to taking either progesterone or stilboestrol than they did during the control period.
The fact that we assayed only two of the three major metabolites of promazine undoubtedly diminished our ability to derive as dear a distinction between certain categories of subjects as it was possible to make in respect to the pethidine study.
DISCUSSION
The presence in the urine of an excess of unchanged pethidine over the demethylated compound, and of a relatively large quantity of unchanged promazine plus "major metabolites", indicates, in all probability, that the subject has a diminished capacity to metabolize these drugs at a rate which is within the normal range. With these criteria in mind, the results obtained from this preliminary study encourage us to draw the following conclusions:
(i) Pregnancy-possibly from its inception-is associated with a diminution in the ability of the subject to metabolize certain drugs.
(ii) Administration of oral contraceptive agents can promote a similar deficiency.
(iii) The newly-born infant (and thus, probably the foetus) at the very least reflects the deficiency of the mother as noted in (i) above.
(iv) The administration of stilboestrol tends to provoke this diminution in metabolizing capacity.
(v) The administration of progesterone to males appears to diminish the capacity of these subjects to metabolize the drugs.
(vi) No effect due to the total, or merely functional, loss of the ovaries in this regard can be convincingly demonstrated.
It is not our purpose here to discuss, by inference, the possible ways by which these changes are wrought. Mueller and Kappas (1964) have suggested that the natural oestrogens, during pregnancy and when given in excess to the nonpregnant subject, interfere with the transport of certain materials (including sulphobromophthalein) through the liver cell. More recently Kleiner, Kresch and Arias (1965) have shown that a similar picture is seen in subjects who are taking Enavid. If indeed the presence of an excess of female sex hormone made it more difficult for an agent such as pethidine to gain entry to the hepatic cell-or to the microsomes within that cell (Booth and Gillette, 1962 )-there to be metabolized, this would fit well with many of the conclusions noted in the previous paragraph.
The fact that the responses shown by subjects on oral contraceptives resemble so closely those seen in the pregnant patients lends further substance to the comment made by Tyler (1964) . He suggested that the use of progestogen-oestrogen oral therapy leads to a state of metabolic pseudopregnancy. As the condition is apparently reversed subsequent to the pregnancy, presumably it is also reversible by stopping the administration of the contraceptive agent.
Regarding subjects who are taking oral contraceptives, however, it seems pertinent to make the following observation. A diminution in the capacity to metabolize a drug almost certainly implies that a standard dose of drug will produce a response of longer duration (and possibly of greater total "quantity") than will the same dose given to a normal subject. Thus it would seem advisable to reduce the usual schedule of dosage of certain drugs when treating patients who are in receipt of oral contraceptives. The recently published article by Fletcher, Miya and Bousquet (1965) supports this view. These workers noted that the administration of oestradiol to male rats significantly potentiated the hypothermic response to chlorpromazine in the animals by inducing a reduction in the rate of metabolism of the phenothiazine.
Next, a point may be made respecting the newborn infant. There has developed over the past few years a considerable literature regarding the relative enzymatic deficiency of the neonate and its consequent inefficiency to metabolize certain drugs (Driscoll and Hsia, 1958; Jondorf, Maichel and Brodie, 1959; Han et al., 1962) . The reports upon which these views are based have been derived almost solely from animal studies, and often the species has been the rat. Not uncommonly, it has been observed that the animal begins within a few days after birth to exhibit a metabolic res-ponse more akin to that of the adult. In the human, an outstanding example is provided by the relaxant drugs. Many observers have suggested that the newborn infant is relatively resistant to the action of the depolarizing relaxants and is more sensitive to the curare-like compounds than is the adult (Bush and Stead, 1962; Churchill-Davidson and Wise, 1964; Lim, Davenport and Robson, 1964) . There is no good agreement regarding at what age the response of the infant to the relaxants begins more to resemble that of the adult-estimates vary from 10 days to 8 months. In this context," it is of interest to note that Churchill-Davidson and Wise (1963) have likened ±e response of the neonate to that of the myasthenic patient, and that Frenkel and Ehrlich (1964) have demonstrated that the administration of progesterone to the myasthenic patient induces an increase in the severity of the myasthenic state. It would be quite wrong to suggest here that the neonate does not have a deficiency of the enzymes required to metabolize certain drugs (indeed, our results, as recorded in tables I and II, suggest that the neonates excrete an even greater proportion of received drug unchanged than do the mothers), but it does seem proper to suggest that to a considerable degree the response of the neonate is governed by the excessive quantity of maternally-derived sex hormones present in its tissues during the week or two following the delivery.
In conclusion, we would point out that the processes with which we have so far been concerned are demethylation, (of pethidine) and, possibly, either oxidation or hydroxylation (of promazine beyond the stage of "major metabolites"). It would be unreasonable to suppose that these are the only processes of detoxication and metabolic degradation to be influenced by changes in the environmental concentration of progestogenoestrogen type substances. A study to map a spectrum of such interference is under way.
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